Analysts expect GSK's RSV vaccine Arexvy to power future growth, stemming worries about the strength of its pipeline of drugs in development and costly U.S. litigation over discontinued heartburn drug Zantac. Arexvy, launched in the United States recently, is expected to garner full-year sales of between 900 million pounds to 1 billion pounds ($1.22 billion), GSK said. The London-listed drugmaker said it now expects a rise of 17% to 20% in annual adjusted earnings per share, excluding the effect
Demand for groceries and other necessary household items has remained strong as rising expenses forced consumers to cut discretionary spending, pointing to a change in spending patterns after years of COVID-related disruption. "We also expect the consumer environment to remain challenging with customers continuing to cut back on non-essential items looking ahead in FY24," CEO Brad Banducci said.
Indian Morning Briefing: Asian Markets Mixed morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.